» Articles » PMID: 26656492

A Novel Role for CARM1 in Promoting Nonsense-mediated MRNA Decay: Potential Implications for Spinal Muscular Atrophy

Overview
Specialty Biochemistry
Date 2015 Dec 15
PMID 26656492
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Loss of 'Survival of Motor Neurons' (SMN) leads to spinal muscular atrophy (SMA), a disease characterized by degeneration of spinal cord alpha motor neurons, resulting in muscle weakness, paralysis and death during early childhood. SMN is required for assembly of the core splicing machinery, and splicing defects were documented in SMA. We previously uncovered that Coactivator-Associated Methyltransferase-1 (CARM1) is abnormally up-regulated in SMA, leading to mis-regulation of a number of transcriptional and alternative splicing events. We report here that CARM1 can promote decay of a premature terminating codon (PTC)-containing mRNA reporter, suggesting it can act as a mediator of nonsense-mediated mRNA decay (NMD). Interestingly, this pathway, while originally perceived as solely a surveillance mechanism preventing expression of potentially detrimental proteins, is now emerging as a highly regulated RNA decay pathway also acting on a subset of normal mRNAs. We further show that CARM1 associates with major NMD factor UPF1 and promotes its occupancy on PTC-containing transcripts. Finally, we identify a specific subset of NMD targets that are dependent on CARM1 for degradation and that are also misregulated in SMA, potentially adding exacerbated targeting of PTC-containing mRNAs to the already complex array of molecular defects associated with this disease.

Citing Articles

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice.

Kordala A, Stoodley J, Ahlskog N, Hanifi M, Garcia Guerra A, Bhomra A EMBO Mol Med. 2023; 15(11):e17683.

PMID: 37724723 PMC: 10630883. DOI: 10.15252/emmm.202317683.


Coactivator-associated arginine methyltransferase 1: A versatile player in cell differentiation and development.

Ma Z, Lyu X, Qin N, Liu H, Zhang M, Lai Y Genes Dis. 2023; 10(6):2383-2392.

PMID: 37554200 PMC: 10404874. DOI: 10.1016/j.gendis.2022.05.021.


NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis.

Adami R, Bottai D Int J Mol Sci. 2022; 23(23).

PMID: 36499528 PMC: 9736802. DOI: 10.3390/ijms232315209.


Carm1 and the Epigenetic Control of Stem Cell Function.

Saber J, Rudnicki M Stem Cells Transl Med. 2022; 11(11):1143-1150.

PMID: 36103286 PMC: 9672848. DOI: 10.1093/stcltm/szac068.


Protein Arginine Methyltransferases in Neuromuscular Function and Diseases.

Lee J, An S, Lee S, Kang J Cells. 2022; 11(3).

PMID: 35159176 PMC: 8834056. DOI: 10.3390/cells11030364.


References
1.
Ruggiu M, McGovern V, Lotti F, Saieva L, Li D, Kariya S . A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol. 2011; 32(1):126-38. PMC: 3255708. DOI: 10.1128/MCB.06077-11. View

2.
Sanchez G, Dury A, Murray L, Biondi O, Tadesse H, El Fatimy R . A novel function for the survival motoneuron protein as a translational regulator. Hum Mol Genet. 2012; 22(4):668-84. DOI: 10.1093/hmg/dds474. View

3.
Tani H, Torimura M, Akimitsu N . The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells. PLoS One. 2013; 8(1):e55684. PMC: 3559549. DOI: 10.1371/journal.pone.0055684. View

4.
Gregoretti C, Ottonello G, Chiarini Testa M, Mastella C, Rava L, Bignamini E . Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013; 131(5):e1509-14. DOI: 10.1542/peds.2012-2278. View

5.
Metze S, Herzog V, Ruepp M, Muhlemann O . Comparison of EJC-enhanced and EJC-independent NMD in human cells reveals two partially redundant degradation pathways. RNA. 2013; 19(10):1432-48. PMC: 3854533. DOI: 10.1261/rna.038893.113. View